Search all medical codes

Unclassified drugs or biologicals

HCPCS code

Name of the Procedure:

  • Common Name: Unclassified drugs or biologicals
  • Technical/Medical Term: HCPCS Code C9399

Summary

In layman's terms, this refers to the administration of drugs or biological agents that don't have a specific classification in the Healthcare Common Procedure Coding System (HCPCS). These are often new or rare treatments not yet classified into standard categories.

Purpose

  • Medical Conditions/Problems Addressed: This may be used for a variety of conditions, particularly when treating unique, complex, or rare diseases.
  • Goals/Expected Outcomes: The goal is to provide customized therapeutic options that aren't covered by an existing HCPCS code, addressing unique patient needs and conditions effectively.

Indications

  • Symptoms/Conditions Warranting the Procedure: Conditions that require non-standard, individualized treatments, complicated medical issues, or rare diseases.
  • Patient Criteria: Patients with conditions that haven't responded to standard treatments or require a novel therapeutic approach.

Preparation

  • Pre-Procedure Instructions: Patients might be asked to follow specific instructions depending on the drug or biological being administered. This could include fasting, adjusting current medications, or avoiding certain foods.
  • Diagnostic Tests/Assessments: Depending on the treatment, the physician may order blood tests, imaging studies, or other assessments to determine the patient's suitability for the unclassified drug or biological.

Procedure Description

  • Step-by-Step Explanation:
    1. The healthcare provider will explain the unclassified drug or biological being used.
    2. Pre-administration assessments are carried out.
    3. The medication is prepared and checked for accuracy.
    4. The drug or biological is administered via the appropriate route (e.g., intravenous, intramuscular, subcutaneous).
    5. The patient is monitored for any immediate reactions.
  • Tools/Equipment/Technology Used: Syringes, IV equipment, infusion pumps, or other administration devices.
  • Anesthesia or Sedation: Generally not required, though local anesthesia might be applied if needed.

Duration

The duration can vary widely depending on the drug or biological being administered but typically can range from a few minutes to several hours.

Setting

These procedures are generally performed in a hospital, outpatient clinic, or specialized infusion center.

Personnel

  • Healthcare professionals involved include physicians, nurses, pharmacists, and potentially a specialized infusion team.

Risks and Complications

  • Common Risks: Mild allergic reactions, discomfort at the administration site.
  • Rare But Serious Risks: Severe allergic reactions (anaphylaxis), infection, incorrect dosage administration. Management involves immediate medical intervention with emergency drugs and supportive care.

Benefits

Expected benefits include targeted treatment for difficult-to-treat or rare conditions that conventional medications fail to manage. The benefits may become evident within days to weeks, depending on the drug or biological used.

Recovery

  • Post-Procedure Care: Patients might stay for observation for any adverse reactions.
  • Expected Recovery Time: Minimal recovery time; patients can often resume normal activities shortly after, unless the specific treatment requires otherwise.
  • Follow-Up: Regular follow-up appointments may be necessary to monitor the treatment's effectiveness and adjust dosing.

Alternatives

  • Other Treatment Options: Standard drugs or biologicals classified under existing HCPCS codes.
  • Pros and Cons: While standard treatments might have more extensive safety profiles and established protocols, unclassified drugs or biologicals offer the advantage of personalized treatment. However, they may carry more unknown risks due to their novel nature.

Patient Experience

  • During: Patients might feel a pinch or mild discomfort at the injection site, potential for mild side effects like nausea or dizziness.
  • After: Patients are monitored for any adverse effects and given instructions on how to manage mild side effects at home. Pain management strategies and comfort measures are provided as necessary.

Medical Policies and Guidelines for Unclassified drugs or biologicals

Related policies from health plans

Adbry (tralokinumab)
Complement Inhibitors
Dupixent (dupilumab)
Dupixent (dupilumab)
Growth Hormone
Growth Hormone
Imcivree (setmelanotide)
Palynziq (pegvaliase-pqpz)
Spevigo (spesolimab-sbzo)
Tegsedi (inotersen)
Tegsedi (inotersen)
Uplizna (inebilizumab-cdon)
Voxzogo (vosoritide)
Lantidra

Similar Codes